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Abstract: Purpose Multidisciplinary management improves complex treatment decision making in cancer
care, but its impact for bladder cancer (BC) has not been documented. Although radical cystectomy
(RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-
based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor,
chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treat-
ment option. In the absence of randomized studies, this study compared the oncologic outcomes between
patients treated with RC or TMT by using a propensity score matched-cohort analysis. Methods Data
from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were
reviewed retrospectively. Those who received TMT for MIBC were identified and matched (for sex, cT
and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treatment date,
age, carcinoma in situ status, and hydronephrosis) with propensity scores to patients who underwent
RC. Overall survival and disease-specific survival (DSS) were assessed with Cox proportional hazards
modeling and a competing risk analysis, respectively. Results A total of 112 patients with MIBC were
included after matching (56 who had been treated with TMT, and 56 who underwent RC). The median
age was 68.0 years, and 29.5% had stage cT3/cT4 disease. At a median follow-up of 4.51 years, there were
20 deaths (35.7%) in the RC group (13 as a result of BC) and 22 deaths (39.3%) in the TMT group (13
as a result of BC). The 5-year DSS rate was 73.2% and 76.6% in the RC and TMT groups, respectively (
P = .49). Salvage cystectomy was performed in 6 (10.7%) of 56 patients who received TMT. Conclusion
In the setting of a MDBCC, TMT yielded survival outcomes similar to those of matched patients who
underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to discuss
various treatment options, including organ-sparing TMT.
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A B S T R A C T
Purpose
Multidisciplinary management improves complex treatment decision making in cancer care, but its
impact for bladder cancer (BC) has not been documented. Although radical cystectomy (RC) cur-
rently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-
based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder
tumor, chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as
a valid treatment option. In the absence of randomized studies, this study compared the oncologic
outcomes between patients treated with RC or TMT by using a propensity score matched-cohort
analysis.
Methods
Data from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013
were reviewed retrospectively. Thosewho received TMT forMIBCwere identiﬁed andmatched (for
sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score,
treatment date, age, carcinoma in situ status, and hydronephrosis) with propensity scores to pa-
tients who underwent RC. Overall survival and disease-speciﬁc survival (DSS) were assessed with
Cox proportional hazards modeling and a competing risk analysis, respectively.
Results
A total of 112 patients with MIBCwere included after matching (56 who had been treated with TMT,
and 56who underwent RC). Themedian agewas 68.0 years, and 29.5% had stage cT3/cT4 disease.
At a median follow-up of 4.51 years, there were 20 deaths (35.7%) in the RC group (13 as a result of
BC) and 22 deaths (39.3%) in the TMT group (13 as a result of BC). The 5-year DSS rate was 73.2%
and 76.6% in the RC and TMT groups, respectively (P = .49). Salvage cystectomy was performed in
6 (10.7%) of 56 patients who received TMT.
Conclusion
In the setting of aMDBCC, TMT yielded survival outcomes similar to those of matched patients who
underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to
discuss various treatment options, including organ-sparing TMT.
J Clin Oncol 35:2299-2305. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Bladder cancer (BC) care can be complex. Vari-
ation in assessment of pathologic stage, grade, and
histologic subtype, quality of care,1,2 or utilization
of perioperative chemotherapy3,4 affect manage-
ment and outcomes.5 Multidisciplinary care (MDC)
models have been shown to maximize outcomes
by minimizing such variability, which reduces
judgment errors and optimizes communication
among physicians and between caregivers and
patients.6-9 MDC provides an opportunity for
all treatment options to be discussed, which is
important for BC care, in which multiple treat-
ment options are available to patients regardless of
the stage at presentation.
The traditional treatment of muscle-invasive
bladder cancer (MIBC) has been radical cystectomy
(RC). Bladder-sparing strategies have emerged as
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a valid treatment option during the past decades. Recent data
from many noncomparative single-arm series and Radiation
Therapy Oncology Group protocols demonstrated that selected
patients with MIBC experience excellent outcomes and experi-
ence preservation of a functioning bladder with trimodal therapy
(TMT), which consists of debulking transurethral resection of
bladder tumor (TURBT), chemotherapy for radiation sensiti-
zation, and external beam radiotherapy.10-13 To date, only one
small, nonadjusted, case-control series of TMT versus RC in
MIBC has been reported, which demonstrated no difference
between groups.14 A propensity score adjusted direct comparison
of TMT to RC in MIBC has not been reported.
Radiotherapy alone, radiotherapy and concurrent cisplatin
chemotherapy, or neoadjuvant chemotherapy (NAC) followed by
radiotherapy have been performed for more than three decades at
the Princess Margaret Cancer Centre, University Health Network
(UHN), Toronto, Canada.11 The increasing complexity of treat-
ment decisions and the need to offer various treatment options,
including RC and TMT, for eligible patients with MIBC were
recognized, and a weekly multidisciplinary bladder cancer clinic
(MDBCC) was established at the center in 2008. This study aimed
to assess changes in care plans after multidisciplinary assessment
and to compare oncologic outcomes between patients with MIBC
who were treated with RC or TMT in the MDBCC by using
a propensity score analysis.
METHODS
MDBCC Overview
The MDBCC was initiated as a weekly, referral-based outpatient
clinic held in the cystoscopy suite of UHN, where patients with complex
BC cases were referred for evaluation and second opinion by a multidis-
ciplinary team that specialized in BC. Administrative coordinators pre-
pared a summary of patient data, which included pathology review and
imaging, before the patients’ clinic visits. Clinical information was
summarized in the bladder informatics tool (eCancerCareBladder), as
reported previously.15
In the MDBCC, all patients were evaluated by a multidisciplinary
team composed of one of four urologic oncologists (G.S.K., N.E.F.,
M.A.S.J., A.R.Z.) and one of four radiation oncologists (P.C., R.G.B., M.M.,
P.W.), all of whom have expertise in BC care.16 A BC expert medical
oncologist (S.S.S.) was available for immediate, same-day consultation.
Pathology review by expert genitourinary (GU) pathologists was initiated
in case of initial assessment by a non-GU pathologist, variant histology, or
doubt of the TURBTstage. Patient assessment involved a thorough history
and physical examination, detailed review of external reports and available
imaging, and cystoscopic evaluation with surgical and radiation oncolo-
gists in attendance. After multidisciplinary discussion, consensus rec-
ommendations for additional investigations (eg, pathology review by
uropathology, additional imaging, and/or transurethral reresections) or
deﬁnitive treatment were made.
MDBCC Patients
All consecutive patients with BC referred to the MDBCC between
April 2008 and December 2012 were identiﬁed retrospectively and in-
cluded in the study to assess the impact of additional investigations and
treatment decision in the clinic, and patients were identiﬁed and included
up to December 2013 for the propensity score analysis. Baseline parameters
of patients were recorded from electronic hospital charts. Electronically
archived referral letters were used to identify the initial proposed treatment
plan. Post-MDBCC disease stage and deﬁnitive treatment were recorded.
Posttreatment outcome results were retrieved from electronic hospital
charts. Institutional research ethics board approval was obtained (REB
10-0367-CE, 15-8727-CE).
Treatment
After clinic assessment and review of additional investigations and/or
data (when necessary), ﬁnal treatment decisions were presented to the
patient with all physicians present. Patients with metastatic disease (re-
gional and systemic) were referred for primary chemotherapy. Patients
with localized non–muscle-invasive bladder cancer (NMIBC) were offered
additional reresection, intravesical therapy, RC, radiotherapy, or enroll-
ment in clinical trials. Patients with localized, nonmetastatic MIBC were
assessed for their candidacy for TMT, RC, and/or clinical trials. RC
consisted of cystoprostatectomy in men or anterior exenteration in women
with bilateral pelvic lymph node dissection (template at the surgeon’s
discretion) and urinary diversion (ileal conduit, ileal neobladder, or
Indiana pouch).
Patients with a history of pelvic radiotherapy who underwent RC
were excluded from the propensity score analysis, because they would not
be eligible for both treatment modalities. Candidates for TMT had (1)
tumors, 5 cm, (2) solitary tumors, (3) minimal to no hydronephrosis, (4)
good bladder function, and (5) no multifocal carcinoma in situ (CIS).
Patients with limited CIS adjacent to the primary tumor and mild
hydronephrosis, and patients at high risk for RC morbidity and mortality
were not excluded from TMT consideration. If patients were candidates for
TMT and RC, both were discussed, and the discussion included expected
outcomes and complications.
The merits of perioperative chemotherapy using a shared decision-
making process (NAC for patients who received TMT, NAC v adjuvant
chemotherapy [AC] for patients who underwent RC) were discussed with
patients. The criteria for cisplatin-based NAC were an Eastern Cooperative
Oncology Group (ECOG) status , 2, creatinine clearance . 60 mL/min,
no grade 2 or worse hearing loss or neuropathy, and adequate cardiac
function (less than New York Heart Association class III heart failure).17 In
addition to NAC criteria, AC was only offered to patients who underwent
RC and who had pathologic stage pT3/4 and/or N+. NAC and AC consisted
of four cycles of gemcitabine plus cisplatin. A debulking TURBT to remove
all visible tumor was performed before concomitant chemoradiotherapy.
Radio-opaque contrast (0.5-1 mL Lipiodol [ethiodized oil, Guerbet LLC,
Bloomington, IN]) was injected cystoscopically at the periphery of the
tumor resection site for radiation treatment planning and to facilitate
radiation delivery. Daily image-guided intensity-modulated radiotherapy
was delivered to the bladder and pelvic nodes to a dose of 46 Gy in 23
fractions with a sequential tumor boost of 20 Gy in 10 fractions (total, 66
Gy). Radiosensitization with concurrent single-agent cisplatin chemo-
therapy (40 mg/m2) was administered weekly during therapy.
Follow-Up
All patients were observed by a standardized protocol of clinic visits
(quarterly visits in year 1, biannual visits in years 2 and 3, and annual visits
thereafter). Visits involved history, physical examination, blood work, and
urinary cytology. Patients who received TMT or RC underwent axial
imaging (computed tomography or magnetic resonance imaging) bi-
annually to detect recurrent disease and complications. Patients who
received TMTalso underwent cystoscopy and salvage RC if they developed
MIBC. Random bladder biopsy was not routine. Intravesical therapy and
the management of NMIBC intravesical recurrence were based on
established guidelines.18-21
Outcomes
The immediate impact of MDBCC on BC management was assessed
by determining how often MDBCC assessment changed the initial tumor
stage and/or treatment plan. Any change in clinical tumor stage and/or
2300 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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treatment plan that resulted from MDBCC assessment was recorded.
Change in treatment was attributed to revised stage and/or expert opinion.
Overall survival (OS) and disease-speciﬁc survival (DSS) for patients who
received TMTwere compared with those propensity-matched patients who
underwent RC.
Statistical Analyses
Short-term changes in stage and treatment plan were reported with
descriptive statistics for continuous variables (means and medians) and
categoric variables (percentages). To assess long-term outcomes, pro-
pensity score matching of patients treated with TMT to patients treated
with RC at the UHN from 2008 to 2013 was performed.22 Only patients
who had urothelial-predominant BC were included. Pretreatment clinical
variables used for matching and for the propensity score analysis are
detailed in the Appendix (online only). Patients were observed until death,
loss to follow-up, or August 2016, when data were censored. OS and DSS
comparisons were depicted as Kaplan-Meier and cumulative incidence
plots, respectively. Multivariable Cox proportional hazards modeling and
competing risk models, which accounted for clustering given the matched
nature of the data, were used to compare OS and DSS in the TMTand RC
groups, respectively.
RESULTS
MDBCC Patient Demographics and Impact
Characteristics of the 248 patients referred to the MDBCC
from 2008 to 2012 are listed in Table 1; most patients were referred
by urologists for a second opinion or for consideration of bladder
preservation with TMT for MIBC. After MDBCC assessment,
treatment recommendations were immediately possible for 51
patients (21%). The remaining 197 patients (79%) required
additional investigation to recommend a ﬁnal treatment plan. As
a result of these additional measures 89 (36%) of the 197 patients
had a change in tumor stage (Fig 1)—20 (44%) of 45 patients from
repeat TURBT, 47 (34%) of 137 patients from additional imaging,
and 22 (17%) of 133 patients as a result of pathology review. Many
patients had more than one investigation that contributed to stage
change.
Eight (16%) of the 51 patients for whom additional in-
vestigations were not recommended received a change in treatment
plan based on multidisciplinary consultation and expert opinion.
Likewise, 19 (10%) of the 197 patients whose disease warranted
additional investigations were advised about alternative treatment
despite a lack of stage change on repeat investigation. Overall,
additional investigations provided data that altered treatment
recommendations 58 times, which resulted in treatment changes
for 56 patients (23%). A total of 83 patients (33% of all MDBCC
attendees) were given different treatment plans after multidisci-
plinary consultation (56 patients who were reinvestigated with
stage change, 19 patients who were reinvestigated without stage
change, and eight patients without reinvestigation).
The ﬁnal treatments provided were stratiﬁed as follows: RC
was performed on 74 patients (30%); 80 patients (32%) were
treated with radiotherapy, with or without chemotherapy; thirty-
ﬁve patients (14%) were treated with intravesical therapy; 21 pa-
tients (9%) received cystoscopic surveillance; 26 (10%) received
palliation. Other treatments were provided to 12 patients (5%). Of
the 80 patients who underwent radiotherapy, 24 (30%) were
deemed unﬁt for cystectomy on the basis of a comorbid status,
whereas 56 (70%) were candidates for cystectomy but chose
bladder preservation.
Comparison Between TMT and RC: Propensity Matched
Analysis
Of the 162 patients with MIBC, 49 of the 80 who received
radiation-based therapy received full TMT (ie, maximal TURBT
plus external-beam radiotherapy plus concomitant chemother-
apy). The remaining 31 patients were either ineligible for cisplatin
chemotherapy (ie, received radiation monotherapy), did not re-
ceive maximal TURBT, or had a disease with nonurothelial his-
tology. To expand the cohort, 10 consecutive patients who received
TMT from 2013 were added, which provided a total of 59 patients.
Fifty-six patients had data that could be propensity matched to
our institutional cystectomy database (2008 to 2013) with ex-
cellent matching characteristics and balance (Table 2). Appendix
Figure A1 (online only) shows propensity scores after patients were
matched, which demonstrates similarities between study groups.
Rates of perioperative chemotherapy were well balanced with
37.5% (19.6% neoadjuvant and 17.9% adjuvant) and 35.7% (all
neoadjuvant) in the RC and TMT groups, respectively.
The median OS was 6.61 years, and there were no differences
in OS (P = .63) or DSS (P = .49) on univariable analysis (Fig 2).
Multivariable analysis that adjusted for cTand cN staging, presence
of hydronephrosis, CIS, age, sex, ECOG status, and Charlson
comorbidity score did not reveal signiﬁcant differences in OS
(TMT: hazard ratio [HR], 0.85; 95% CI, 0.43 to 1.66; P = .63) or
DSS (TMT: HR, 0.92; 95% CI, 0.41 to 2.04; P = .83; data not
shown). The 5-year expected DSS rates for RC and TMT were
Table 1. Characteristics of Patients Assessed in the MDBCC From
2008 to 2012
Characteristic
No. (%) of Patients
(N = 248)
Sex
Male 192 (77)
Female 56 (33)
Median age, years (range) 71 (37-95)
Stage at presentation
NMI (Ta, T1, Tis) 78 (32)
MI (T2, T3, T3)* 162 (65)
Tx 5 (2)
PCA 3 (1)
Referring specialty
Urology 203 (82)
Family medicine 21 (8)
Medical oncology 10 (4)
Radiation oncology 7 (3)
Other 7 (3)
Reason for referral
Second opinion 165 (67)
Unusualy histology 15 (6)
Radical cystectomy 15 (6)
TMT chemoradiation 50 (20)
Other 3 (1)
Abbreviations: MDBCC, multidisciplinary bladder cancer clinic; MI, muscle
invasive; NMI, non–muscle invasive; PCA, prostate cancer; TMT, trimodal
therapy; Tx, stage undetermined.
*Patient data considered for subsequent propensity score comparison.
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73.2% and 76.6%, respectively (P = .49). At a median follow-up of
4.51 years, there were 20 deaths (35.7%; 13 as a result of BC) in the
RC group and 22 deaths (39.3%; 13 as a result of BC) in the TMT
group (P = .84).
The overall recurrence rates in the RC and TMT groups
were 38% and 59%, respectively. Isolated intravesical recurrence
occurred in 17 (30.3%) of patients who received TMT, with 12
(21.4%) treated by endoscopic resection with or without intra-
vesical bacillus Calmette-Gue´rin therapy. The salvage cystectomy
rate for the TMT group was 10.7%, and no cystectomy was re-
quired for bladder toxicity.
DISCUSSION
No randomized trials have directly compared RC and bladder
preservation approaches with TMT, so there is a lack of level-1
evidence to guide patient management. The recent United King-
dom phase III trial, Selective Bladder Preservation Against Radical
Excision (SPARE), unfortunately failed to accrue patients and
resulted in premature closure.23 Most series of bladder preserva-
tion, with few exceptions,12,13 have included a limited number of
cases per center, which compounds the lack of randomized
data.10,24
To overcome the limitations of published noncomparative
retrospective studies, this study used propensity score matching
with patients who underwent contemporary RC to generate
comparable groups using stringent criteria. The data showed that
TMT provides midterm survival outcomes comparable to RC in
selected BC cases. This analysis supports the concept that multi-
disciplinary consultation with experts in BC care leads to im-
provements in BC staging, which may optimize treatment
recommendations. Indeed, the MDBCC assessment resulted in
treatment changes for 33% of referred patients, but, in the absence
of a true control group, better outcomes remain unproven. In-
correct clinical staging, especially understaging, has been identiﬁed
as a serious problem in BC, and improvements in the staging
process are needed to achieve more accuracy and improved care for
patients with BC.5,25
MDC enables assessment by multiple disciplines, with sub-
sequent provision of specialty-speciﬁc input, enhances the likeli-
hood of delivering optimal curative therapy26, adds an additional
layer of checks and balances in the decision-making process to
minimize errors in judgment, and maximizes the probability of
MDBCC
(N = 248)
No additional investigations
(n = 51; 21%)
Additional investigations
(n = 197; 79%)
Treatment change
(n = 8)
Re-TURBT
(n = 45; 23%)
Stage change
(n = 20; 44%)
Treatment change
(n = 15) 
Imaging
(n = 137; 70%)
Stage change
(n =  47; 34%)
Treatment change
(n = 25)
Pathology review
(n = 133; 68%)
Stage change
(n = 22; 17%)
Treatment change
(n = 18)
Fig 1. Changes in care and treatment plan
after multidisciplinary bladder cancer clinic as-
sessment of patients seen between 2008 and
2012. MDBCC, multidisciplinary bladder cancer
clinic; Re-TURBT, repeat transurethral resection
of bladder tumor.
Table 2. Propensity Matched Characteristics of Patients With MIBC Un-
dergoing Radical Cystectomy Versus Trimodal Therapy Chemoradiation
Characteristic
No. (%) of Patients
Cystectomy
(n = 56)
Chemoradiation
(n = 56)
Age at diagnosis, years
# 60 14 (25) 12 (21.4)
. 60 42 (75) 44 (78.6)
Sex
Male 41 (73.2) 40 (71.4)
Female 15 (26.8) 16 (28.6)
T stage
Organ conﬁned (cT # 2) 41 (73.2) 38 (67.9)
Not organ conﬁned (cT . 2) 15 (26.8) 18 (32.1)
N stage
cN0/Nx 46 (82.1) 46 (82.1)
cN+ (cN1, cN2, cN3) 10 (17.9) 10 (17.9)
CIS
Absent 38 (67.9) 39 (69.6)
Present 18 (32.1) 17 (30.4)
Hydronephrosis
Absent 49 (87.5) 48 (85.7)
Present 7 (12.5) 8 (14.3)
ECOG performance status
0 40 (71.4) 40 (71.4)
$ 1 16 (28.6) 16 (28.6)
Charlson comorbidity score
# 4 39 (69.6) 37 (66.1)
. 4 17 (30.4) 19 (33.9)
Treatment date
# 2010 30 (53.6) 24 (42.9)
. 2010 26 (46.4) 32 (57.1)
Abbreviations: CIS, carcinoma in situ; ECOG, Eastern Cooperative Oncology
Group; MIBC, muscle-invasive bladder cancer.
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adopting treatment strategies that are based on the highest levels of
evidence.27 Data from oncologic literature in other cancer types6,8,9
support improved survival outcomes in patients who receive care
via multidisciplinary team approaches, and this may also be the
case for patients with BC.
Despite the purported beneﬁts of MDC in oncology, its uptake
in BC has been slow and may be responsible for some degree of
undertreatment of many patients with MIBC. For example, a re-
cent observational study that used propensity score analysis to
compare the effectiveness of AC versus observation post cys-
tectomy in 5,653 patients with pathologic T3-4 and/or pathologic
node-positive BC demonstrated that a mere 23% received AC. AC
was associated with improved survival in patients with locally
advanced BC (HR, 0.70; 95% CI, 0.64 to 0.76).28 Similar underuse
of NAC in patients with MIBC has been reported.26,27 Data from
the SEER-Medicare database on MIBC treatment show that
a disturbing 51% of patients did not receive any deﬁnitive ther-
apy.28 Many of these patients may have been eligible for some form
of multimodal therapy, although they may have been ineligible for
RC.
Critics of TMT point to its potential lack of efﬁcacy compared
with RC or the absence of long-term data. A pooled analysis of six
historical Radiation Therapy Oncology Group single-arm studies
demonstrated a similar 5-year DSS rate of 71% compared with
modern MIBC cystectomy series.10 However, cystectomy series are
not limited to select patients with smaller, unifocal tumors without
CIS or hydronephrosis in which 5-year DSS rates with surgery may
be closer to 80%,29,30 so robust or deﬁnitive conclusions are
limited. Furthermore, although contemporary TMT series involve
more highly selected populations, historical RT series have in-
cluded a large proportion of patients not suitable for RC because
of age, comorbidities, and/or disease extent, which could explain
lower-than-expected survival rates in these series; this difference
further clouds potential comparisons.
In this study, the near identical 5-year DSS for RC and TMT
are in keeping with modern MIBC outcomes reported in cys-
tectomy series31,32 and demonstrate excellent and comparable
results of modern TMT in selected patients with MIBC. The series
had a 10.7% salvage cystectomy rate for high-risk NMIBC and
MIBC recurrences after TMT. The lack of toxicity-related cys-
tectomies supports the tolerability of the regimen. The success of
TMT requires the expertise not only of radiation and medical
oncologists to deliver treatment but also of urologic oncologists
experienced in surveying postradiation bladders (in which dif-
ferentiation between posttreatment radiation changes and tumor
recurrence is not always straightforward) and who can safely
perform salvage cystectomy.
Limitations of this study include its retrospective nature and
the associated selection bias, which confounds by indication. To
overcome this, propensity-matching techniques were applied to
create comparable TMT and RC cohorts. Even with this meth-
odology, unknown confounders may not be accounted for. Nev-
ertheless, balanced, matched comparisons were created on the
basis of clinical factors (cT and cN stage, age, comorbidity,
hydronephrosis, and CIS) that are widely reported to inﬂuence
outcome (Appendix Fig A1). Second, the number of patients
included in the propensity score analysis was limited. The study
included only 112 patients, so larger cohorts are required to
validate the results, because limited statistical power may have
contributed to the statistically nonsigniﬁcant comparisons. The
DSS and OS rates were nearly identical between surgery and
chemoradiation at 5 years (DSS, 73% v 77%, respectively), so it
seems rather unlikely that expansion of the cohort size would
dramatically modify these initial ﬁndings. Third, the median
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Fig 2. Propensity score matched survival outcomes of patients after radical cystectomy versus trimodality therapy chemoradiation. (A) Kaplan-Meier curve of overall
survival (adjusted for treatment, TMT v RC); and (B) cumulative incidence function for disease-speciﬁc survival. BC, bladder cancer; OS, overall survival; RC, radical
cystectomy; TMT, trimodal therapy.
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follow-up of 4.51 years may be considered limited, although, in
patients with BC, pertinent clinical outcomes are often reached
with this length of follow-up. Fourth, we had no quality-of-life data
but have initiated the collection of these data. Fifth, this is a single-
institution study, and there is the possibility that different centers
may experience different outcomes. Sixth, because the study lacked
a true control arm of non-MDBCC care we cannot deﬁnitively
prove that changes we implemented in care as a result of multi-
disciplinary consultation resulted in improved care. Change in
stage was used as a surrogate for appropriate treatment delivery.
Finally, the best method by whichMDC should be provided cannot
be determined from this report. In the MDBCC, assessment and
consultation occur in parallel, with multiple specialists providing
input simultaneously, although BC medical oncologists and expert
GU pathologists were not physically present in the clinic at the
same time. Lack of a full multidisciplinary complement in the same
physical space did not affect their input. Speciﬁcally, we have
increased use of NAC from 7.7% to 47.6% with MDBCC initia-
tion,27 and well over half of the patients undergo pathologic
specimen review, which suggests that this limitation does not
preclude MDC. In our clinic, cystoscopic assessment of patients
treated with TMT by urologic and radiation oncologists present
simultaneously enables joint decision making regarding the need
for additional investigations and/or procedures. Whether this
model provides improved outcomes compared with consultations
done sequentially is unclear. Optimal outcomes, we believe, can be
achieved through multidisciplinary collaboration by GU-trained
oncology caregivers, regardless of how care is provided.
In conclusion, the advantage of MDC is the ability to review
all treatment options with patients in an unbiased fashion. We
observed a change in tumor staging in more than a third of patients
after review in the MDBCC with subsequent modiﬁcations of the
initial treatment plans. These results show that selected patients
who undergo TMT experience outcomes similar to those who
undergo RC. Patients eligible for TMT should be offered the
opportunity to discuss all therapeutic alternatives before treatment
is selected. Rather than pitting surgery against TMT, choice of the
right therapeutic option for the right patient with BC in the setting
of MDC should be encouraged.
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Appendix
Methods
Technical statistical appendix. A total of 59 patients who underwent trimodal therapy (TMT) for bladder cancer (BC) in
amultidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were identiﬁed. These patients werematched to patients who
underwent radical cystectomy (RC) during the same time frame, via propensity scores. Speciﬁcally, a logistic regression propensity
score model of the type of treatment modality received (TMT v RC) was created, and the following variables were included in the
model: age, sex, cT and cN stage (clinical TNM stage), presence of carcinoma in situ (CIS), presence of hydronephrosis, Eastern
Cooperative Onoclogy Group (ECOG) status, Charlson comorbidity score, and treatment date. Matching across the two groups was
achieved with a 0.2-width caliper of the standard deviation of the logit of the propensity scores to reduce bias because of
confounding. The propensity score distributions for the groups both before and after matching are shown in Appendix Figure A1;
Figure A1A demonstrates an initial dissimilarity across the two groups on the basis of propensity score distributions. However, after
matching, the distributions of the propensity scores for the two groups (Appendix Fig A1B) were quite homogeneous and
demonstrated the adequacy of the propensity score model to achieve balance. Table 2 also depicts the similarity across groups after
propensity score matching.
To compare overall survival in both groups, a multivariable Cox proportional hazards model was created to estimate the hazard
of death as a result of BC after adjustment for other risk factors. The same variables used to generate the propensity score (ie, age,
sex, cTand cN stage [clinical TNM stage], presence of CIS, presence of hydronephrosis, ECOG status, Charlson comorbidity score,
and treatment date) were included as covariates in the model. Because of the paired nature of the 1:1 matched data, matched
identify of the pairs as a cluster variable was used. This gave robust estimates of variance for the correlated matched data.
In the case of the competing risk regression for disease-speciﬁc survival, correlated matched pairs were accounted for by using
competing risk regression for clustered data. This method extends the proportional hazards model of Fine and Gray for sub-
distribution to accommodate situations in which the failure times within a cluster might be correlated, because the study subjects
from the same cluster share common factors (Fine JP, Gray RJ: J Am Stat Assoc 94:496-509, 1999). This model directly assesses the
effect of covariates on the subdistribution of a particular type of failure in a competing risk setting. Again, covariates included in the
competing risk model were age, sex, cT and cN stage (clinical TNM stage), presence of CIS, presence of hydronephrosis, ECOG
status, Charlson comorbidity score, and treatment date.
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Fig A1. Propensity score distributions (A) before matching, and (B) after matching. RC, radical cystectomy; TMT, trimodal therapy.
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